This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled,
dose-ranging study will evaluate the safety, tolerability, PK and PD of AG10 compared to
placebo administered on a background of stable heart failure therapy. Screening and
randomization will be followed by a 28-day blinded, placebo-controlled treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
Eidos Therapeutics Eidos Therapeutics, a BridgeBio company